Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
- PMID: 38844800
- PMCID: PMC11156627
- DOI: 10.1038/s41523-024-00650-6
Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
Erratum for
-
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.NPJ Breast Cancer. 2022 Aug 29;8(1):98. doi: 10.1038/s41523-022-00467-1. NPJ Breast Cancer. 2022. PMID: 36038616 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources